Date: 2012-11-28
Type of information: Collaboration agreement
Compound: pharmaceutical co-crystals
Company: Hovione (Portugal) Solvias (Switzerland)
Therapeutic area:
Type agreement: collaboration
services
Action mechanism:
Disease:
Details: Hovione and Solvias have announced the establishment of a collaboration focused on the development and GMP supply of pharmaceutical co-crystals. This strengthens Hovione’s expertise and experience in overcoming drug delivery challenges and also the supply of GMP materials from phase I to commercial scale, with Solvias’ excellence in solid state chemistry. Hovione offers a series of innovative particle engineering technologies focused on amorphous solid dispersions, crystal design and reduction and control of particle size. The collaboration provides Hovione access to Solvias’ co-crystallization expertise and capabilities, thus reinforcing and complementing the crystal design solutions to overcome poor bioavailability and other drug delivery challenges. Solvias continues its strategy of partnering to enhance access to its solid-state solutions.
Financial terms:
Latest news:
